Wade McMonagle is the Director Specialty Care & Oncology for the biopharmaceutical company AbbVie, that focuses on discovering, developing, and delivering medicines in therapeutic areas including immunology, oncology, virology and neuroscience.
Wade has over 20 years experience in the pharmaceutical and medicines industry, previously having worked at Pfizer, including 6 years at the US headquarters in New York with roles in commercial, business development and licensing. A key focus was on the clinical development programs for medicines moving into phase 3, the largest and last stage of clinical trials before medicines are registered and made available to patients.
Wade holds an Executive MBA from the Australian Graduate School of Management (AGSM) and a Bachelor of Science degree from the University of Queensland. He is also a member of the advisory group to the CEO of Medicines Australia.